M254 / J&J  >>  Phase 2
Welcome,         Profile    Billing    Logout  

1 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
M254 / J&J
NCT03866577 / 2018-003534-32: Safety and Tolerability of M254 in Healthy Volunteers and Immune Thrombocytopenic Purpura (ITP) Patients

Terminated
1/2
50
Europe, US
Biological: M254, Placebo, Intravenous immunoglobulin (IVIg)
Momenta Pharmaceuticals, Inc.
Immune Thrombocytopenic Purpura (ITP)
06/21
06/21

Download Options